文献速递乳房整形与再造瘢痕与激光

体外冲击波治疗改善乳房再造术后纤维化:一项随机对照盲法临床试验

Extracorporeal shockwave therapy improves post-breast reconstruction fibrosis: A randomized controlled blinded clinical trial.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2025-09-09

该单盲随机对照试验纳入40例乳房再造术后临床诊断纤维化的成年女性,比较体外冲击波治疗(ESWT)与假治疗(每周两次共八次、随访三个月)的效果。结果显示ESWT组在乳房柔软度、疼痛、纤维化大小、观察者评估及超声组织质量上均显著优于对照组,提示其可带来强且持续的治疗获益。

要点

  • ESWT可显著改善乳房再造术后纤维化患者的乳房柔软度与疼痛。
  • ESWT还缩小纤维化病灶并改善超声下纤维化深度与边界定义。
  • 观察者评估的乳房硬度与整体意见也显著 favoring ESWT。

核心结论

  • ESWT显著改善乳房再造术后纤维化患者的疼痛、柔软度、病灶大小及超声纤维化特征,显示出强且持续的治疗获益。

研究设计与样本

  • 单盲随机对照临床试验,纳入40例临床诊断乳房再造术后纤维化的成年女性,随机接受ESWT或假治疗,每周两次共八次、持续四周,随访三个月。

主要发现

  • 乳房柔软度平均变化ESWT组为4.92 ± 1.86,对照组为0.9 ± 1.48,p = 0.00003。
  • 疼痛平均变化ESWT组为-2.00 ± 2.28,对照组为+0.43 ± 2.16,p = 0.0052。
  • 纤维化大小平均变化ESWT组为3.88 ± 1.82,对照组为0.86 ± 1.59,p = 0.0015。
  • 观察者评估乳房硬度平均变化ESWT组为-2.12 ± 1.55,对照组为-0.14 ± 1.77,p = 0.0013;整体意见平均变化ESWT组为-2.04 ± 1.78,对照组为-0.43 ± 1.74,p = 0.0003。
  • 超声纤维化深度平均变化ESWT组为1.08 ± 0.74,对照组为0.57 ± 0.51,p = 1.57 × 10⁻⁵;边界定义平均变化ESWT组为1.23 ± 0.65,对照组为0.29 ± 0.47,p = 5.30 × 10⁻⁵。

临床怎么用

  • 对于乳房再造术后纤维化患者,可考虑采用ESWT作为非侵入性干预以改善柔软度、疼痛及超声纤维化特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibrosis following breast reconstruction is a debilitating syndrome characterized by (1) restricted shoulder and upper extremity mobility, (2) chronic pain and discomfort, (3) poor tissue pliability, and (4) suboptimal aesthetic outcomes. This condition significantly impairs the quality of life and functional recovery. Currently, no therapeutics directly target fibrotic remodeling. Extracorporeal shockwave therapy (ESWT) uses targeted acoustic pulses to stimulate cellular regeneration, collagen remodeling, and tissue softening, and may offer a novel non-invasive intervention. METHODS: A single-blinded randomized controlled clinical trial was conducted in 40 adult women with clinically diagnosed postoperative fibrosis following breast reconstruction. Participants were randomized to receive either ESWT or sham treatment, delivered in eight biweekly sessions over four weeks, with follow-up at three months. The primary outcome was patient-reported breast softness. Secondary outcomes included pain, fibrosis size, shoulder mobility, observer assessments, and ultrasound-based tissue quality. RESULTS: Compared to the placebo group, the ESWT group demonstrated significantly greater improvements in breast softness (mean change: 4.92 ± 1.86 vs. 0.9 ± 1.48; p = 0.00003), pain (-2.00 ± 2.28 vs. +0.43 ± 2.16; p = 0.0052), and fibrosis size (3.88 ± 1.82 vs. 0.86 ± 1.59; p = 0.0015). Observer-rated outcomes also favored the treatment, including breast firmness (-2.12 ± 1.55 vs. -0.14 ± 1.77; p = 0.0013) and overall opinion (-2.04 ± 1.78 vs. -0.43 ± 1.74; p = 0.0003). Ultrasound scores improved across all metrics, including fibrosis depth (1.08 ± 0.74 vs. 0.57 ± 0.51; p = 1.57 × 10⁻⁵) and boundary definition (1.23 ± 0.65 vs. 0.29 ± 0.47; p = 5.30 × 10⁻⁵). CONCLUSION: ESWT significantly improved pain, softness, lesion size, and sonographic fibrosis features in patients with post-reconstruction fibrosis, demonstrating strong and sustained therapeutic benefit. CLINICAL TRIAL REGISTRATION: NCT06919042.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Nguyen AT, Chon J, Li RA, et al. Extracorporeal shockwave therapy improves post-breast reconstruction fibrosis: A randomized controlled blinded clinical trial. J Plast Reconstr Aesthet Surg. 2025. PMID: 41038043. doi:10.1016/j.bjps.2025.08.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。